Skip to main content
Journal cover image

Concurrent cisplatin, 5-FU, paclitaxel, and radiation therapy in patients with locally advanced esophageal cancer.

Publication ,  Journal Article
Roof, KS; Coen, J; Lynch, TJ; Wright, C; Fidias, P; Willett, CG; Choi, NC
Published in: Int J Radiat Oncol Biol Phys
July 15, 2006

PURPOSE: Phase I-II data regarding neoadjuvant cisplatin, 5-fluorouracil (5-FU), paclitaxel, and radiation (PFT-R) from our institution demonstrated encouraging pathologic complete response (pCR) rates. This article updates our experience with PFT-R, and compares these results to our experience with cisplatin, 5-FU, and radiation therapy (PF-R) in locally advanced esophageal cancer. PATIENTS AND METHODS: We searched the Massachusetts General Hospital cancer registry for esophageal cancer patients treated with radiation therapy and chemotherapy between 1994-2002. Records of patients treated with curative, neoadjuvant therapy were examined for chemotherapeutic regimen. Outcomes of patients treated with PF-R or PFT-R were assessed for response to therapy, toxicity, and survival. RESULTS: A total of 177 patients were treated with neoadjuvant therapy with curative intent; 164 (93%) received PF-R (n=81) or PFT-R (n=83). Median overall survival was 24 months. After a median follow-up of 54 months for surviving patients, 3-year overall survival was 40% with no significant difference between PF-R (39%) and PFT-R (42%). CONCLUSIONS: Our findings failed to demonstrate an improvement in pCR or survival with PFT-R vs. PF-R. These results do not support this regimen of concurrent neoadjuvant PFT-R in esophageal cancer, and suggest that further investigations into alternative regimens and novel agents are warranted.

Duke Scholars

Published In

Int J Radiat Oncol Biol Phys

DOI

ISSN

0360-3016

Publication Date

July 15, 2006

Volume

65

Issue

4

Start / End Page

1120 / 1128

Location

United States

Related Subject Headings

  • Retrospective Studies
  • Paclitaxel
  • Oncology & Carcinogenesis
  • Middle Aged
  • Male
  • Humans
  • Fluorouracil
  • Female
  • Esophageal Neoplasms
  • Drug Administration Schedule
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Roof, K. S., Coen, J., Lynch, T. J., Wright, C., Fidias, P., Willett, C. G., & Choi, N. C. (2006). Concurrent cisplatin, 5-FU, paclitaxel, and radiation therapy in patients with locally advanced esophageal cancer. Int J Radiat Oncol Biol Phys, 65(4), 1120–1128. https://doi.org/10.1016/j.ijrobp.2006.02.013
Roof, Kevin S., John Coen, Thomas J. Lynch, Cameron Wright, Panos Fidias, Christopher G. Willett, and Noah C. Choi. “Concurrent cisplatin, 5-FU, paclitaxel, and radiation therapy in patients with locally advanced esophageal cancer.Int J Radiat Oncol Biol Phys 65, no. 4 (July 15, 2006): 1120–28. https://doi.org/10.1016/j.ijrobp.2006.02.013.
Roof KS, Coen J, Lynch TJ, Wright C, Fidias P, Willett CG, et al. Concurrent cisplatin, 5-FU, paclitaxel, and radiation therapy in patients with locally advanced esophageal cancer. Int J Radiat Oncol Biol Phys. 2006 Jul 15;65(4):1120–8.
Roof, Kevin S., et al. “Concurrent cisplatin, 5-FU, paclitaxel, and radiation therapy in patients with locally advanced esophageal cancer.Int J Radiat Oncol Biol Phys, vol. 65, no. 4, July 2006, pp. 1120–28. Pubmed, doi:10.1016/j.ijrobp.2006.02.013.
Roof KS, Coen J, Lynch TJ, Wright C, Fidias P, Willett CG, Choi NC. Concurrent cisplatin, 5-FU, paclitaxel, and radiation therapy in patients with locally advanced esophageal cancer. Int J Radiat Oncol Biol Phys. 2006 Jul 15;65(4):1120–1128.
Journal cover image

Published In

Int J Radiat Oncol Biol Phys

DOI

ISSN

0360-3016

Publication Date

July 15, 2006

Volume

65

Issue

4

Start / End Page

1120 / 1128

Location

United States

Related Subject Headings

  • Retrospective Studies
  • Paclitaxel
  • Oncology & Carcinogenesis
  • Middle Aged
  • Male
  • Humans
  • Fluorouracil
  • Female
  • Esophageal Neoplasms
  • Drug Administration Schedule